Dendritic Cell Surface Molecules

Hart, Derek N.J.; Clark, Georgina J.; Dekker, Job; Fearnley, D.B.; Kato, Masato; Hock, Barry D.; McLellan, Alexander D.; Neil, Teresa K.; Sorg, R. V.; Sorg, Ursula R.; Summers, Kelly L.; Vučković, Slavica

doi:10.1007/978-1-4757-9966-8_72

Cited by 9 publications

(9 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This possibility is supported by our findings showing that in the thymus of PSGL-1-deficient mice, DCs express higher levels of MHC class II molecules and, accordingly, the percentage of CD4 ϩ CD25 ϩ Foxp3 ϩ T cells is significantly diminished. In this sense, it has already been suggested in the literature that thymic DCs might be the APC responsible for the induction of central tolerance (4,43,44).…”

Section: Discussionmentioning

confidence: 90%

“…The turnover of these cells has been studied in detail. Immature blood DCs migrate toward tissues, mainly skin and other epithelia, to accomplish tissue replenishment (4,5). Under environmental danger signals (infection, inflammation, tissue damage), these cells capture Ags and migrate toward the regional lymph nodes.…”

mentioning

confidence: 99%

“…This migration is accompanied by a maturation process, increasing the expression of MHC class II molecules and costimulatory receptors and becoming highly immunogenic (1,2,4,5). In contrast, in steady-state conditions, tissue DCs remain immature, exhibiting a high internalization capability, a reduced expression of molecules involved in Ag presentation, and a very low immunogenic capability (1,2,4,5). When these immature DCs interact with T lymphocytes, they induce anergy or deletion, acting as negative regulators of the immune response (6).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Functional Role of P-Selectin Glycoprotein Ligand 1/P-Selectin Interaction in the Generation of Tolerogenic Dendritic Cells

Urzainqui

Hoyo

Lamana

et al. 2007

The Journal of Immunology

View full text Add to dashboard Cite

Dendritic cells (DCs) have a key role in both the generation of the immune response and the induction of tolerance to self-Ags. In this work, the possible role of P-selectin glycoprotein ligand 1 (PSGL-1) on the tolerogenic activity of human DCs was explored. We found that the engagement of PSGL-1 by P-selectin on DCs induced the expression of c-Fos, IDO, IL-10, and TGF-β genes. Remarkably, stimulation of DCs through PSGL-1 with P-selectin enhanced their capability to generate CD4+CD25+Foxp3+ regulatory T cells, which expressed high levels of TGF-β1 mRNA, synthesized IL-10, and suppressed the proliferation of autologous CD4+CD25− T cells. Accordingly, we found that DCs from PSGL-1−/− mice expressed higher levels of MHC class II molecules, and exhibited an enhanced immunogenicity compared with wild-type mice. In addition, the percentage of CD4+CD25+Foxp3+ regulatory T cells in the thymus of PSGL-1-deficient animals was significantly reduced. Our data reveal an unexpected role of PSGL-1 on the tolerogenic function of DCs, and the regulation of the immune response.

show abstract

Section: Discussionmentioning

confidence: 90%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Functional Role of P-Selectin Glycoprotein Ligand 1/P-Selectin Interaction in the Generation of Tolerogenic Dendritic Cells

Urzainqui

Hoyo

Lamana

et al. 2007

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…In humans, DC were first identified as HLA-DR + interstitial cells in the kidney [1] followed by descriptions of tissue resident HLA-DR + cells in the tonsil and other non-lymphoid organs [2][3][4]. Subsequent studies defined them in bone marrow, blood, tonsil, lymph node and spleen as well as the gut and respiratory tract [5]. It was soon recognised that studies of human DC populations would require first, a convenient source and means of purifying this rare population and secondly, specific cell surface markers and monoclonal antibodies (mAb) to identify them.…”

Section: Introductionmentioning

confidence: 99%

Screening of the HLDA9 panel on peripheral blood dendritic cell populations

Ding

Azlan

et al. 2011

Immunology Letters

View full text Add to dashboard Cite

“…Co-stimulatory molecules such as CD80, CD86 and CD40 are expressed at low levels on steady-state DCs [11]. Subsets of DCs express Fcg receptor (CD16, CD32 and CD64), complement receptors CD11 c (CR4), CD11 b (CR3) and CD88 (CR5 a), and lectin receptors [12,13]. Blood DCs express high levels of the skin homing molecule, cutaneous leukocyte antigen (CLA) [14] and L-selectin [1,6].…”

mentioning

confidence: 99%

Dendritic Cells and Cancer: Prospects for Cancer Vaccination

Hart

Jackson²,

Nestle³

2002

Cancer Immune Therapy

View full text Add to dashboard Cite

Effective therapeutic cancer vaccination is an old dream, now rekindled by modern advances in cell biology and immunology. Several key facts have inspired the current optimism for clinical immunotherapy trials. First, the realization that, by definition, every malignant cell must express at least one gene product in an abnormal fashion means that theoretically there is at least one tumor-associated antigen (TAA) (it may be an autoantigen) available as a target. Secondly, we now know that any cellular protein (membrane, cytoplasmic or nuclear) may be presented as a peptide, in the context of major histocompatibility complex (MHC) molecules, for recognition by the T lymphocyte receptor complex. Thirdly, whilst it is clear that the immune response has failed the cancer patient, it is also true that it has not suffered irreversible meltdown, i. e. deletion of tumor-reactive T lymphocytes. Finally, it is now recognized that dendritic cells (DCs) are the key cellular elements for initiating and directing immune responses. As DC biology appears to be abnormal in cancer patients, the simplest hypothesis of the day is to use activated DCs to present relevant TAAs to the patient's immune system and thus generate an effective therapeutic response. This chapter will review the physiology of DC biology in the cancer patient, DC preparations and clinical trial results, whilst predicting areas requiring attention in order to optimize DC cancer vaccination for future patient benefit. DC PropertiesDCs originate from CD34 + hematopoietic stem cells, circulate in peripheral blood and are found in virtually all tissues of the body. In peripheral blood, DCs are a morphologically heterogeneous cell population, including DCs with membrane processes (ªmyeloid DCº) and DCs with plasmacytoid morphology (ªplasmacytoid monocytesº, ªplasmacytoid T lymphocyteº, ªlymphoid DCsº) [1,2]. In the skin, DCs are present as epidermal Langerhans cells (LCs) with their characteristic Birbeck ISBNs: 3-527-30441-X (Hardback);(Electronic) 3-527-60079-5 granules [3] and dermal DCs [4,5], which have a subtly different morphology and phenotype. In secondary lymphoid tissues they are present as interdigitating DCs with prominent membrane processes in the T cell area and as ªplasmacytoid monocytesº around high endothelial venules (HEVs) [6]. Monocytes may also differentiate directly into DC-like cells in sites of inflammation [7]. Whilst there is some uncertainty about the identity of the different DC populations and their differentiation, it is clear that a variety of growth factors and cytokines drive DC development [8]. Furthermore, chemokines direct their migration [9] and other soluble compounds influence their function.Blood DCs are commonly defined as lineage negative (Lin ± ), MHC class II positive (MHC-II + ) cells, lacking the CD14 (monocyte), CD3 (T cell), CD19 (B cell) and CD56 [natural killer (NK) cell] lineage markers, but expressing MHC class II molecules at high density, on their surface. They express various adhesion molecules including CD11 a ...

show abstract

Dendritic Cell Surface Molecules

Cited by 9 publications

References 20 publications

Functional Role of P-Selectin Glycoprotein Ligand 1/P-Selectin Interaction in the Generation of Tolerogenic Dendritic Cells

Functional Role of P-Selectin Glycoprotein Ligand 1/P-Selectin Interaction in the Generation of Tolerogenic Dendritic Cells

Screening of the HLDA9 panel on peripheral blood dendritic cell populations

Dendritic Cells and Cancer: Prospects for Cancer Vaccination

Contact Info

Product

Resources

About